Lane 1: Wild-type B16F10 whole cell lysate.
Lane 2: MLH1 knockout B16F10 whole cell lysate.
ET1604-41 was shown to specifically react with MLH1 in wild-type B16F10 cells. No band was observed when MLH1 knockout samples were tested. Wild-type and MLH1 knockout samples were subjected to SDS-PAGE. Proteins were transferred to a PVDF membrane and blocked with 5% NFDM in TBST for 1 hour at room temperature. The primary Anti-MLH1 antibody (ET1604-41, 1/1,000) and Anti-Vinculin antibody (ET1705-94, 1/5,000) were used in 5% BSA at room temperature for 2 hours. Goat Anti-Rabbit IgG H&L (HRP) Secondary Antibody (HA1001) at 1:200,000 dilution was used for 1 hour at room temperature.
Recombinant Rabbit monoclonal primary
MLH1 Recombinant Rabbit Monoclonal Antibody [SP08-04] (ET1604-41)
Synthetic peptide within human mlh1 aa 707-756 / 756.
Daudi cell lysate, K562 cell lysate, A431 cell lysate, HL-60 cell lysate, HepG2, B16F10, rat large intestine tissue, human tonsil tissue, mouse testis tissue, Hela.
Store at +4C after thawing. Aliquot store at -20C or -80C. Avoid repeated freeze / thaw cycles.
1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.
Protein A affinity purified.
Use at an assay dependent concentration.
COCA 2 antibody; COCA2 antibody; DNA mismatch repair protein Mlh1 antibody; FCC 2 antibody; FCC2 antibody; hMLH 1 antibody; hMLH1 antibody; HNPCC 2 antibody; HNPCC antibody; HNPCC2 antibody; MGC5172 antibody; MLH 1 antibody; MLH1 antibody; MLH1_HUMAN antibody; MutL homolog 1 (E. coli) antibody; MutL homolog 1 antibody; MutL homolog 1 colon cancer nonpolyposis type 2 antibody; MutL homolog 1, colon cancer, nonpolyposis type 2 (E. coli) antibody; MutL protein homolog 1 antibody; MutL, E. coli, homolog of, 1 antibody
Belongs to the DNA mismatch repair MutL/HexB family.
Colon, lymphocytes, breast, lung, spleen, testis, prostate, thyroid, gall bladder and heart.
DNA-mismatch repair (MMR) is an essential process in maintaining genetic stability. Lack of a functional DNA-mismatch repair pathway is a common characteristic of several different types of human cancers, either due to an MMR gene mutation or promoter methylation gene silencing. MLH1 is an integral part of the protein complex responsible for mismatch repair and is expressed in lymphocytes, heart, colon, breast, lung, spleen, testis, prostate, thyroid and gall bladder tissues, and is methylated in several ovarian tumors. Loss of MLH1 protein expression is associated with a mutated phenotype, microsatellite instability and a predisposition to cancer. In hereditary nonpolyposis colorectal cancer (HNPCC), an autosomal dominant inherited cancer syndrome that signifies a high risk of colorectal and various other types of cancer, the MLH1 gene exhibits a pathogenic mutation. Certain cancer cell lines, including leukemia CCRF-CEM, colon HCT 116 and KM12, and ovarian cancers SK-OV-3 and IGROV-1, show complete deficiency of MLH1, while MLH1 is expressed in 60% of melanomas, 70% of noninvasive squamous cell carcinomas and 30% of invasive squamous cell carcinomas.